Analysis of Albumin-Associated Peptides and Proteins from Ovarian Cancer Patients
- 1 October 2005
- journal article
- conference paper
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 51 (10) , 1933-1945
- https://doi.org/10.1373/clinchem.2005.052944
Abstract
Background: Albumin binds low–molecular-weight molecules, including proteins and peptides, which then acquire its longer half-life, thereby protecting the bound species from kidney clearance. We developed an experimental method to isolate albumin in its native state and to then identify [mass spectrometry (MS) sequencing] the corresponding bound low–molecular-weight molecules. We used this method to analyze pooled sera from a human disease study set (high-risk persons without cancer, n= 40; stage I ovarian cancer, n = 30; stage III ovarian cancer, n = 40) to demonstrate the feasibility of this approach as a discovery method. Methods: Albumin was isolated by solid-phase affinity capture under native binding and washing conditions. Captured albumin-associated proteins and peptides were separated by gel electrophoresis and subjected to iterative MS sequencing by microcapillary reversed-phase tandem MS. Selected albumin-bound protein fragments were confirmed in human sera by Western blotting and immunocompetition. Results: In total, 1208 individual protein sequences were predicted from all 3 pools. The predicted sequences were largely fragments derived from proteins with diverse biological functions. More than one third of these fragments were identified by multiple peptide sequences, and more than one half of the identified species were in vivo cleavage products of parent proteins. An estimated 700 serum peptides or proteins were predicted that had not been reported in previous serum databases. Several proteolytic fragments of larger molecules that may be cancer-related were confirmed immunologically in blood by Western blotting and peptide immunocompetition. BRCA2, a 390-kDa low-abundance nuclear protein linked to cancer susceptibility, was represented in sera as a series of specific fragments bound to albumin. Conclusion: Carrier-protein harvesting provides a rich source of candidate peptides and proteins with potential diverse tissue and cellular origins that may reflect important disease-related information.This publication has 42 references indexed in Scilit:
- CA125: Holy Grail or a Poisoned ChaliceNephron Clinical Practice, 2005
- The role of CA125 in clinical practiceJournal of Clinical Pathology, 2005
- Phosphoproteomic Analysis of the Developing Mouse BrainMolecular & Cellular Proteomics, 2004
- Proteome Analysis of DNA Damage-induced Neuronal Death Using High Throughput Mass SpectrometryJournal of Biological Chemistry, 2004
- Proteomic Analysis of the Intestinal Epithelial Cell Response to Enteropathogenic Escherichia coliJournal of Biological Chemistry, 2004
- Direct interaction of the Fanconi anaemia protein FANCG with BRCA2/FANCD1Human Molecular Genetics, 2003
- The human serum proteome: Display of nearly 3700 chromatographically separated protein spots on two‐dimensional electrophoresis gels and identification of 325 distinct proteinsProteomics, 2003
- Genetic Heterogeneity and Penetrance Analysis of the BRCA1 and BRCA2 Genes in Breast Cancer FamiliesAmerican Journal of Human Genetics, 1998
- The Amino-Terminal Peptide of HIV-1 gp41 Interacts with Human Serum AlbuminAIDS Research and Human Retroviruses, 1993
- Purification of heterotrimeric GTP-binding proteins from brain: identification of a novel form of GoBiochemistry, 1988